Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

BACKGROUND: AZD8931 has equipotent activity against epidermal growth factor receptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II dose (RP2D) of AZD8931 + chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophag...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Anne, Virdee, Pradeep S., Eatock, Martin, Lord, Simon R., Falk, Stephen, Anthoney, D. Alan, Turkington, Richard C., Goff, Matthew, Elhussein, Leena, Collins, Linda, Love, Sharon, Moschandreas, Joanna, Middleton, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947485/
https://www.ncbi.nlm.nih.gov/pubmed/31765988
http://dx.doi.org/10.1016/j.ejca.2019.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947485/
https://www.ncbi.nlm.nih.gov/pubmed/31765988
http://dx.doi.org/10.1016/j.ejca.2019.10.010

Ejemplares similares